ExpreS2ion provides update on its expectations to the COVID-19 vaccine program prior to the Q2 2020 report
Hørsholm, Denmark, August 19, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby updates the market on its expectations to the development timelines of the COVID-19 vaccine prior to the release of the Company’s Q2 2002 report. The Company now expects the phase III trials to commence as soon as the first half of 2021, with possible market launch before the end of 2021.The Company previously announced that the PREVENT-nCoV consortium, in which the Company is a partner, plans to enter the first clinical Phase I/IIa trial before the end of 2020, with headline results